Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) is gaining investor attention as a next-generation biopharmaceutical company developing advanced immune-strengthening therapeutics for some of the world’s most critical diseases, including HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, and Diabetes .
The autonomous vehicle revolution has officially moved beyond concept and into real-world deployment. In major U.S. cities including Phoenix, San Francisco, Los Angeles, and Austin, fully driverless robotaxi fleets operated by Waymo, Cruise, and Tesla are already transforming urban mobility.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
New note provides greater repayment flexibility and less dilution with elimination of mandatory amortization payments, increased conversion floor price to $0.35, and expanded mandatory ELOC payments from 33% to 50%
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
As year-end positioning accelerates, the traditional Santa’s Rally is shining a spotlight on small-cap and micro-cap stocks under $5 showing renewed momentum, rising volume, and investor awareness. These names are drawing attention across technology, fintech, media, space, and consumer sectors—areas where speculative capital often rotates during holiday trading weeks.
Data from FDA-advised study demonstrates Lumee™ Oxygen tissue monitoring is a safe and effective long-term method in PAD patients and will support potential FDA submission; strongly correlates with transcutaneous partial pressure of oxygen
EU commercialization expected in early 2026; U.S. entry and expanded indications to follow as digital-health pioneer advances tissue-integrated biosensor platform
Signal Advance, Inc. (OTC: SIGL ) today announced a new milestone in the evolution of cybersecurity: successful validation of its Analog Guard® encryption platform as resistant to advanced artificial intelligence (AI) decryption models. The breakthrough supports Signal Advance’s mission to deliver next-generation, physics-based cybersecurity solutions designed to defend against both AI-driven and quantum-era threats. Listen to CEO Now!
